Division of Immunology, Boston Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston, Mass.
Division of Pediatric Allergy/Immunology, Marmara University, Istanbul, Turkey.
J Allergy Clin Immunol. 2018 Mar;141(3):1050-1059.e10. doi: 10.1016/j.jaci.2017.05.022. Epub 2017 Jun 7.
LPS-responsive beige-like anchor protein (LRBA) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) deficiencies give rise to overlapping phenotypes of immune dysregulation and autoimmunity, with dramatically increased frequencies of circulating follicular helper T (cT) cells.
We sought to determine the mechanisms of cT cell dysregulation in patients with LRBA deficiency and the utility of monitoring cT cells as a correlate of clinical response to CTLA4-Ig therapy.
cT cells and other lymphocyte subpopulations were characterized. Functional analyses included in vitro follicular helper T (T) cell differentiation and cT/naive B-cell cocultures. Serum soluble IL-2 receptor α chain levels and in vitro immunoglobulin production by cultured B cells were quantified by using ELISA.
cT cell frequencies in patients with LRBA or CTLA4 deficiency sharply decreased with CTLA4-Ig therapy in parallel with other markers of immune dysregulation, including soluble IL-2 receptor α chain, CD45ROCD4 effector T cells, and autoantibodies, and this was predictive of favorable clinical responses. cT cells in patients with LRBA deficiency were biased toward a T1-like cell phenotype, which was partially reversed by CTLA4-Ig therapy. LRBA-sufficient but not LRBA-deficient regulatory T cells suppressed in vitro T cell differentiation in a CTLA4-dependent manner. LRBA-deficient T cells supported in vitro antibody production by naive LRBA-sufficient B cells.
cT cell dysregulation in patients with LRBA deficiency reflects impaired control of T cell differentiation because of profoundly decreased CTLA4 expression on regulatory T cells and probably contributes to autoimmunity in patients with this disease. Serial monitoring of cT cell frequencies is highly useful in gauging the clinical response of LRBA-deficient patients to CTLA4-Ig therapy.
脂多糖反应性米色样锚蛋白(LRBA)和细胞毒性 T 淋巴细胞相关抗原 4(CTLA4)缺乏会导致免疫失调和自身免疫的重叠表型,循环滤泡辅助 T(cT)细胞的频率显著增加。
我们旨在确定 LRBA 缺陷患者 cT 细胞失调的机制,以及监测 cT 细胞作为 CTLA4-Ig 治疗临床反应相关性的效用。
对 cT 细胞和其他淋巴细胞亚群进行了特征描述。功能分析包括体外滤泡辅助 T(T)细胞分化和 cT/幼稚 B 细胞共培养。通过酶联免疫吸附试验定量检测血清可溶性白细胞介素 2 受体α链水平和培养 B 细胞的体外免疫球蛋白产生。
LRBA 或 CTLA4 缺乏症患者的 cT 细胞频率随着 CTLA4-Ig 治疗而急剧下降,与其他免疫失调标志物(包括可溶性白细胞介素 2 受体α链、CD45ROCD4 效应 T 细胞和自身抗体)平行,这预示着良好的临床反应。LRBA 缺陷患者的 cT 细胞偏向于 T1 样细胞表型,这部分被 CTLA4-Ig 治疗逆转。LRBA 充分但不是 LRBA 缺陷的调节性 T 细胞以 CTLA4 依赖的方式抑制体外 T 细胞分化。LRBA 缺陷的 T 细胞支持幼稚的 LRBA 充足的 B 细胞体外抗体产生。
LRBA 缺陷患者的 cT 细胞失调反映了调节性 T 细胞中 CTLA4 表达的严重减少,导致 T 细胞分化失控,可能导致该疾病患者的自身免疫。连续监测 cT 细胞频率对于评估 LRBA 缺陷患者对 CTLA4-Ig 治疗的临床反应非常有用。